Novo Nordisk's Buyback Runs Into Lilly's Trial Data as Third-Quarter Print Lands

Novo Nordisk has been steadily mopping up its own stock even as the ground shifts beneath its two flagship franchises. The Danish drugmaker reported purchases of 41,714,179 B-shares for DKK 11,564,364,801 through Monday, part of a programme that permits buybacks of up to DKK 15 billion. The current tranche, which opened on 6 May, authorises up to DKK 11,200,000,010.45 and runs until 1 February 2027 — a ceiling rather than a sum already spent, and one that stacks inside the overall envelope rather than on top of it.

That capital-return machinery answers a balance-sheet question. It says nothing about the one investors are actually asking: whether Novo's medicines can hold their ground against rival offerings. Clinical readouts and regulatory decisions carry far more weight on that front than the pace of share repurchases.

A revenue test before the bell

The immediate checkpoint arrives today, with third-quarter 2026 results scheduled for release before the market opens. Analysts, according to media reports from yesterday, were looking for revenue to decline year on year. That is a forecast of softer trading, not a reported figure — and the distinction matters when the print lands.

Beyond the headline number, attention centres on the floor of the full-year guidance. Jyske Bank, as reported yesterday, expected Novo to lift that lower bound for 2026, citing the rollouts of the Wegovy pill and a stronger-than-anticipated performance from Ozempic. This is an analyst's projection, not a company decision. A projected revenue decline and a friendlier annual outlook are not mutually exclusive; they simply describe the business from different vantage points.

A raised floor would signal a less downbeat read on the current year. It would not, by itself, prove a durable competitive improvement — that would require the operational rationale to hold up. The guidance change is the signal; product momentum determines how far it carries.

Lilly draws a line in the trial data

The competitive backdrop has sharpened. Eli Lilly said on 28 October that its experimental candidate Retatrutide beat Novo's Ozempic in a head-to-head Phase 3 study of adults with type-2 diabetes, with Ozempic dosed at 2 mg. Reuters reported that Retatrutide delivered better blood-sugar control and more than double the weight loss.

The claim comes from a rival, concerns a drug still in development and does not amount to an approval. Even so, a direct comparison puts product performance squarely in the frame — and no buyback can settle a medical contest. The reach of the finding is bounded: Retatrutide is investigational, and the study implies neither an accomplished shift in market share nor a quantifiable revenue hit for Novo. It remains a serious counterpoint to the optimistic guidance thesis, since a near-term improvement in Ozempic would not automatically neutralise longer-run pressure.

Legal friction added to the pile. According to Bloomberg Law, Novo failed on 27 October in a US court bid to block Eli Lilly's comparative advertising for weight-loss medicines.

A regulatory win, and a calendar of scrutiny

On the positive side of the ledger, the FDA on 23 October approved Awiqli as a once-weekly basal insulin for children aged ten and older with type-2 diabetes, aimed at improving blood-sugar control. The approval stands as a regulatory step forward alongside the continuing capital returns — a counterweight, though not an answer, to Lilly's study claim.

If the hoped-for guidance lift materialises and is credibly tied to product development, a brighter read on the year looks plausible. Should it fail to appear, or its reasoning fall short, the bullish case loses traction — though an unchanged outlook alone would not prove further deterioration.

Science then takes over from finance. Novo has flagged twelve presentations on clinical and care data for semaglutide at the Liver Meeting in Denver from 5 to 9 November. Further contributions are slated for ObesityWeek in Washington from 14 to 17 November, covering CagriSema, care data on the Wegovy pill and STEP Young, among others. Announced presentations are not positive results — but they are the next openings to test the product story against the numbers.